2120.HK
Wenzhou Kangning Hospital Co., Ltd. [2120.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
2120.HK Stock Summary
In the News
2120.HK Financial details
Company Rating
Buy
Market Cap
841.38M
Income
-19.26M
Revenue
1.52B
Book val./share
16.66
Cash/share
3.83
Dividend
0.11
Dividend %
0.81%
Employees
4.77K
Optionable
No
Shortable
Yes
Earnings
14 Apr 2024
P/E
-83.89
Forward P/E
-
PEG
5.88
P/S
0.61
P/B
0.77
P/C
2.87
P/FCF
-93.69
Quick Ratio
0.43
Current Ratio
1.21
Debt / Equity
0.75
LT Debt / Equity
0.36
-
-
EPS (TTM)
-0.26
EPS next Y
-
EPS next Q
-
EPS this Y
-124.59%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
14.76%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-8.33%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-
ROE
-1%
ROC
0.05%
Gross Margin
24%
Oper. Margin
7%
Profit Margin
-1%
Payout
-470%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.05-14.5
52W High
-21.57%
52W Low
+22%
RSI
43
Rel Volume
0.07
Avg Volume
28.64K
Volume
2K
Perf Week
-5.34%
Perf Month
6.81%
Perf Quarter
-0.18%
Perf Half Y
-1.96%
-
-
-
-
Beta
0.109
-
-
Volatility
0.18%, 0.47%
Prev Close
-0.18%
Price
10.98
Change
-0.18%
2120.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 10.21 | 11.78 | 14.23 | 17.98 | 19.9 | |
| Net income per share | 1.1 | 0.52 | 0.77 | 0.61 | -0.15 | |
| Operating cash flow per share | 0.91 | 1.52 | 2.76 | 2.69 | 3.05 | |
| Free cash flow per share | -1.08 | -0.22 | 0.16 | 0.21 | -0.13 | |
| Cash per share | -1.13 | 2.82 | 1.42 | 2.75 | 3.78 | |
| Book value per share | 15.35 | 15.94 | 16.73 | 16.62 | 16.11 | |
| Tangible book value per share | 13.7 | 14.74 | 14.91 | 12.58 | 12.92 | |
| Share holders equity per share | 15.35 | 15.94 | 16.73 | 16.62 | 16.11 | |
| Interest debt per share | 3.28 | 7.59 | 9.4 | 11.8 | 11.52 | |
| Market cap | 2.28B | 1.34B | 1.74B | 1.24B | 797.14M | |
| Enterprise value | 2.32B | 1.69B | 2.19B | 1.86B | 1.34B | |
| P/E ratio | 28.23 | 34.97 | 31.21 | 28.08 | -72.67 | |
| Price to sales ratio | 3.05 | 1.55 | 1.69 | 0.95 | 0.54 | |
| POCF ratio | 34.2 | 12.01 | 8.72 | 6.38 | 3.51 | |
| PFCF ratio | -28.81 | -82.25 | 148.78 | 80.5 | -82.27 | |
| P/B Ratio | 2.03 | 1.15 | 1.44 | 1.03 | 0.66 | |
| PTB ratio | 2.03 | 1.15 | 1.44 | 1.03 | 0.66 | |
| EV to sales | 3.11 | 1.96 | 2.12 | 1.44 | 0.9 | |
| Enterprise value over EBITDA | 12.86 | 11.32 | 9.55 | 8.81 | 6.22 | |
| EV to operating cash flow | 34.86 | 15.17 | 10.96 | 9.61 | 5.9 | |
| EV to free cash flow | -29.36 | -103.89 | 187.07 | 121.27 | -138.35 | |
| Earnings yield | 0.04 | 0.03 | 0.03 | 0.04 | -0.01 | |
| Free cash flow yield | -0.03 | -0.01 | 0.01 | 0.01 | -0.01 | |
| Debt to equity | 0.21 | 0.45 | 0.54 | 0.68 | 0.68 | |
| Debt to assets | 0.13 | 0.25 | 0.29 | 0.34 | 0.31 | |
| Net debt to EBITDA | 0.24 | 2.36 | 1.95 | 2.96 | 2.52 | |
| Current ratio | 1.23 | 1.01 | 1.07 | 1.12 | 1.21 | |
| Interest coverage | 11.95 | 2.77 | 5.31 | 2.55 | 2.25 | |
| Income quality | 0.89 | 2.91 | 3.39 | 4.4 | -20.72 | |
| Dividend Yield | 0 | 0.02 | 0.01 | 0.02 | 0.06 | |
| Payout ratio | 0 | 0.76 | 0.31 | 0.69 | -4.7 | |
| Sales general and administrative to revenue | 0.13 | 0.14 | 0.12 | 0.03 | 0.04 | |
| Research and developement to revenue | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Intangibles to total assets | 0.11 | 0.09 | 0.1 | 0.15 | 0.14 | |
| Capex to operating cash flow | -2.19 | -1.15 | -0.94 | -0.92 | -1.04 | |
| Capex to revenue | -0.2 | -0.15 | -0.18 | -0.14 | -0.16 | |
| Capex to depreciation | -3.75 | -1.69 | -2.13 | -1.71 | -2.07 | |
| Stock based compensation to revenue | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 19.52 | 13.7 | 17.02 | 15.11 | 7.3 | |
| ROIC | 0.05 | 0.03 | 0.05 | 0.02 | -0.03 | |
| Return on tangible assets | 0.05 | 0.02 | 0.03 | 0.02 | 0 | |
| Graham Net | -5.84 | -4.84 | -8.88 | -8.52 | -9.57 | |
| Working capital | 111.22M | 4.79M | 41.73M | 64.64M | 135.61M | |
| Tangible asset value | 1B | 1.08B | 1.08B | 907.36M | 963.56M | |
| Net current asset value | -40.39M | -234.35M | -293.74M | -497.26M | -518.83M | |
| Invested capital | 0.21 | 0.45 | 0.54 | 0.68 | 0.68 | |
| Average receivables | 187.24M | 376.84M | 302.25M | 289.43M | 368.2M | |
| Average payables | 85.07M | 77.93M | 72.56M | 69.37M | 77.47M | |
| Average inventory | 22.17M | 22.19M | 30.54M | 47.01M | 57.43M | |
| Days sales outstanding | 183.23 | 160.81 | 79.74 | 99.46 | 94.1 | |
| Days payables outstanding | 59.36 | 42.03 | 34.85 | 26.07 | 27.66 | |
| Days of inventory on hand | 15.39 | 13.11 | 18.79 | 21.3 | 18.81 | |
| Receivables turnover | 1.99 | 2.27 | 4.58 | 3.67 | 3.88 | |
| Payables turnover | 6.15 | 8.68 | 10.47 | 14 | 13.2 | |
| Inventory turnover | 23.72 | 27.84 | 19.43 | 17.13 | 19.41 | |
| ROE | 0.07 | 0.03 | 0.05 | 0.04 | -0.01 | |
| Capex per share | -1.99 | -1.75 | -2.59 | -2.47 | -3.18 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.95 | 5 | 5 | 5.21 | 5.21 | |
| Net income per share | 0.26 | -0.42 | -0.42 | 0.29 | 0.29 | |
| Operating cash flow per share | 0.38 | 1.15 | 1.15 | 0.76 | 0.76 | |
| Free cash flow per share | -0.44 | 0.37 | 0.37 | 0.04 | 0.04 | |
| Cash per share | 3.82 | 3.78 | 3.78 | 3.83 | 3.83 | |
| Book value per share | 16.75 | 16.11 | 16.11 | 16.66 | 16.66 | |
| Tangible book value per share | 12.7 | 12.92 | 12.92 | 13.16 | 13.16 | |
| Share holders equity per share | 16.75 | 16.11 | 16.11 | 16.66 | 16.66 | |
| Interest debt per share | 13.52 | 5.24 | 11.28 | 4.73 | 12.86 | |
| Market cap | 770.42M | 818.12M | 797.14M | 789.16M | 654.92M | |
| Enterprise value | 1.5B | 547.03M | 1.34B | 514.2M | 1.32B | |
| P/E ratio | 9.93 | -6.49 | -6.33 | 9.02 | 7.48 | |
| Price to sales ratio | 2.09 | 2.19 | 2.14 | 2.03 | 1.68 | |
| POCF ratio | 27.53 | 9.55 | 9.31 | 13.89 | 11.53 | |
| PFCF ratio | -23.65 | 29.51 | 28.75 | 274.6 | 227.89 | |
| P/B Ratio | 0.62 | 0.68 | 0.66 | 0.63 | 0.53 | |
| PTB ratio | 0.62 | 0.68 | 0.66 | 0.63 | 0.53 | |
| EV to sales | 4.07 | 1.47 | 3.59 | 1.32 | 3.39 | |
| Enterprise value over EBITDA | 24.49 | 29.81 | 73.05 | 9.14 | 23.43 | |
| EV to operating cash flow | 53.72 | 6.39 | 15.66 | 9.05 | 23.2 | |
| EV to free cash flow | -46.16 | 19.73 | 48.35 | 178.92 | 458.55 | |
| Earnings yield | 0.03 | -0.04 | -0.04 | 0.03 | 0.03 | |
| Free cash flow yield | -0.04 | 0.03 | 0.03 | 0 | 0 | |
| Debt to equity | 0.81 | 0.33 | 0.68 | 0.28 | 0.75 | |
| Debt to assets | 0.37 | 0.15 | 0.31 | 0.13 | 0.34 | |
| Net debt to EBITDA | 11.94 | -14.77 | 29.61 | -4.89 | 11.79 | |
| Current ratio | 1.24 | 1.21 | 1.21 | 1.08 | 1.08 | |
| Interest coverage | 0 | 0 | 0.02 | 0 | 1.77 | |
| Income quality | 1.44 | -2.72 | -2.72 | 2.6 | 2.6 | |
| Dividend Yield | 0.01 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Payout ratio | 0.45 | -0.54 | -0.54 | 0.49 | 0.49 | |
| Sales general and administrative to revenue | 0.12 | 0.14 | 0.14 | 0.13 | 0.13 | |
| Research and developement to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Intangibles to total assets | 0.15 | 0.14 | 0.14 | 0.15 | 0.15 | |
| Capex to operating cash flow | -2.16 | -0.68 | -0.68 | -0.95 | -0.95 | |
| Capex to revenue | -0.16 | -0.16 | -0.16 | -0.14 | -0.14 | |
| Capex to depreciation | -1.98 | -2.17 | -2.17 | -1.92 | -1.92 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | -0.56 | |
| Graham number | 9.9 | 12.37 | 12.37 | 10.48 | 10.48 | |
| ROIC | 0.01 | 0 | 0 | 0.02 | 0.01 | |
| Return on tangible assets | 0.01 | -0.01 | -0.01 | 0.01 | 0.01 | |
| Graham Net | -9.16 | -9.57 | -9.57 | -10.02 | -10.02 | |
| Working capital | 155.9M | 135.61M | 135.61M | 62.65M | 62.65M | |
| Tangible asset value | 947.27M | 963.56M | 963.56M | 981.46M | 981.46M | |
| Net current asset value | -540.81M | -518.83M | -518.83M | -521M | -521M | |
| Invested capital | 0.81 | 0.33 | 0.68 | 0.28 | 0.75 | |
| Average receivables | 0 | 420.4M | 382.84M | 392.43M | 402.02M | |
| Average payables | 0 | 69.47M | 86.27M | 87.01M | 88.16M | |
| Average inventory | 0 | 56.79M | 58.33M | 56.55M | 54.77M | |
| Days sales outstanding | 111.65 | 92.3 | 92.3 | 93.02 | 93.02 | |
| Days payables outstanding | 17.26 | 26.21 | 25.91 | 27.4 | 27.35 | |
| Days of inventory on hand | 18.28 | 17.62 | 17.62 | 17.01 | 17.01 | |
| Receivables turnover | 0.81 | 0.98 | 0.98 | 0.97 | 0.97 | |
| Payables turnover | 5.22 | 3.43 | 3.47 | 3.28 | 3.29 | |
| Inventory turnover | 4.92 | 5.11 | 5.11 | 5.29 | 5.29 | |
| ROE | 0.02 | -0.03 | -0.03 | 0.02 | 0.02 | |
| Capex per share | -0.81 | -0.78 | -0.78 | -0.72 | -0.72 |
2120.HK Frequently Asked Questions
What is Wenzhou Kangning Hospital Co., Ltd. stock symbol ?
Wenzhou Kangning Hospital Co., Ltd. is a CN stock and trading under the symbol 2120.HK
What is Wenzhou Kangning Hospital Co., Ltd. stock quote today ?
Wenzhou Kangning Hospital Co., Ltd. stock price is $10.98 today.
Is Wenzhou Kangning Hospital Co., Ltd. stock public?
Yes, Wenzhou Kangning Hospital Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 28.64K
- Market Capitalization 841.38M
- Employee 4.77K
- CEO Mr. Weili Guan
- Headquarters Wenzhou,CN
- IPO Date 2015-11-20
-
Website
https://www.knhosp.cn 
Wenzhou Kangning Hospital Co., Ltd. operates and manages a network of healthcare facilities in the People's Republic of China. It primarily focuses on providing psychiatric specialty care. The company also provides property leasing and sale services; and software and information technology services, as well as hospital management, forensic authentication, and medical services. It is also engaged in pharmaceutical retail. The company was formerly known as Wenzhou City Kangning Psychiatric Rehabilitation Hospital and changed its name to Wenzhou Kangning Hospital Co., Ltd. in October 2014. Wenzhou Kangning Hospital Co., Ltd. was founded in 1996 and is headquartered in Wenzhou, the People's Republic of China.
